All AbMole products are for research use only, cannot be used for human consumption.
GSK256066 is a selective phosphodiesterase 4 (PDE4)inhibitor with an IC50 of 3.2 pM. Oral phosphodiesterase (PDE)4 inhibitors have demonstrated clinical efficacy in chronic obstructive pulmonary disease and asthma. Preclinical andclinical investigation of inhaled PDE4 inhibitors is ongoing. GSK256066 may have an improved therapeutic index compared with oral PDE4 inhibitors, e.g., cilomilast and roflumilast.GSK256066 demonstrates potent and long-lasting anti-inflammatory effects in animal models of pulmonary inflammation and does not induce emetic episodes in ferrets. GSK256066 has potential as an inhaled therapeutic for the treatment of asthma and chronic obstructive pulmonary disease.
*The compound is unstable in solutions, freshly prepared is recommended
 |
Source | J Pharmacol Exp Ther (2011). Figure 3. GSK256066 |
| Method | i.v. | |
| Cell Lines | mice | |
| Concentrations | 10 μg/kg | |
| Incubation Time | 6 h | |
| Results | GSK256066 and FP inhibited the increase in eosinophil number in the BAL in a dose-dependent fashion |
| Cell Experiment | |
|---|---|
| Cell lines | PBMCs cells line |
| Preparation method | Compound Preparation for In Vitro Assays. Dilution series for pIC50 determinations generally comprised eight successive 3-fold dilutions in DMSO. Low-volume additions (0.5-2.0 μl) to assays were carried out using a Biomek Fx liquid-handling robot (Beckman Coulter, Fullerton, CA).Percentages of inhibition values were generated relative to uninhibited controls. Values for pIC50 were determined from concentration-response curves by nonlinear least-squares curve fitting, in general using a four-parameter logistic equation in Activity Base (IDBS, Guildford, Surrey, UK). |
| Concentrations | 0~10 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | LPS-induced pulmonary neutrophilia in rats model |
| Formulation | 0.2% Tween 80 in normal saline |
| Dosages | 0.1-100 μg/kg |
| Administration | intratracheally |
| Molecular Weight | 518.58 |
| Formula | C27H26N4O5S |
| CAS Number | 801312-28-7 |
| Solubility (25°C) | DMSO 12 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PDE Products |
|---|
| BAY-60-7550
BAY-60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human). |
| Roflumilast
Roflumilast (APTA-2217; BYK 20869; B9302-107) is a novel and selective, long-acting inhibitor of phosphodiesterase 4 (PDE-4). |
| Piclamilast
Piclamilast (RP 73401) is a potent and selective inhibitor of phosphodiesterase (PDE) 4. |
| Apremilast
Apremilast is a novel, orally available small molecule inhibitor of PDE4 with IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM. |
| Sildenafil citrate
Sildenafil citrate is an agent used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
